Frontiers in immunology · 2023
Vitronectin promotes immunothrombotic dysregulation in the venular microvasculature.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Uhl Bernd, Haring Florian, Slotta-Huspenina Julia, Luft Joshua, Schneewind Vera, Hildinger Jonas, Wu Zhengquan, Steiger Katja, Smiljanov Bojan, Batcha Aarif M N, Keppler Oliver T, Hellmuth Johannes C, Lahmer Tobias, Stock Konrad, Weiss Bernhard G, Canis Martin, Stark Konstantin, Bromberger Thomas, Moser Markus, Schulz Christian, Weichert Wilko, Zuchtriegel Gabriele, Reichel Christoph A
Аннотация
Microvascular immunothrombotic dysregulation is a critical process in the pathogenesis of severe systemic inflammatory diseases. The mechanisms controlling immunothrombosis in inflamed microvessels, however, remain poorly understood. Here, we report that under systemic inflammatory conditions the matricellular glycoproteinvitronectin (VN) establishes an intravascular scaffold, supporting interactions of aggregating platelets with immune cells and the venular endothelium. Blockade of the VN receptor glycoprotein (GP)IIb/IIIa interfered with this multicellular interplay and effectively prevented microvascular clot formation. In line with these experimental data, particularly VN was found to be enriched in the pulmonary microvasculature of patients with non-infectious (pancreatitis-associated) or infectious (coronavirus disease 2019 (COVID-19)-associated) severe systemic inflammatory responses. Targeting the VN-GPIIb/IIIa axis hence appears as a promising, already feasible strategy to counteract microvascular immunothrombotic dysregulation in systemic inflammatory pathologies.